NZ597563A - Muc1 antibodies - Google Patents
Muc1 antibodiesInfo
- Publication number
- NZ597563A NZ597563A NZ597563A NZ59756310A NZ597563A NZ 597563 A NZ597563 A NZ 597563A NZ 597563 A NZ597563 A NZ 597563A NZ 59756310 A NZ59756310 A NZ 59756310A NZ 597563 A NZ597563 A NZ 597563A
- Authority
- NZ
- New Zealand
- Prior art keywords
- chain variable
- variable region
- antibody
- disclosed
- heavy chain
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/3076—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells against structure-related tumour-associated moieties
- C07K16/3092—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells against structure-related tumour-associated moieties against tumour-associated mucins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/567—Framework region [FR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Immunology (AREA)
- Pulmonology (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Cell Biology (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Oncology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Hematology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US23021109P | 2009-07-31 | 2009-07-31 | |
| EP09009942A EP2281844A1 (en) | 2009-07-31 | 2009-07-31 | MUC 1 antibodies |
| PCT/EP2010/004663 WO2011012309A1 (en) | 2009-07-31 | 2010-07-30 | Muc1 antibodies |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NZ597563A true NZ597563A (en) | 2013-08-30 |
Family
ID=41460131
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NZ597563A NZ597563A (en) | 2009-07-31 | 2010-07-30 | Muc1 antibodies |
Country Status (17)
| Country | Link |
|---|---|
| US (1) | US9217038B2 (https=) |
| EP (3) | EP2281844A1 (https=) |
| JP (2) | JP5922018B2 (https=) |
| KR (1) | KR101773506B1 (https=) |
| CN (1) | CN102574926B (https=) |
| AR (1) | AR077334A1 (https=) |
| AU (1) | AU2010278302B2 (https=) |
| BR (1) | BR112012002226A2 (https=) |
| CA (1) | CA2768888C (https=) |
| CU (1) | CU23972B1 (https=) |
| EA (1) | EA029954B1 (https=) |
| IL (1) | IL217827A (https=) |
| MX (1) | MX2012000874A (https=) |
| NZ (1) | NZ597563A (https=) |
| SG (2) | SG177527A1 (https=) |
| WO (1) | WO2011012309A1 (https=) |
| ZA (1) | ZA201200166B (https=) |
Families Citing this family (38)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SI2073842T1 (sl) | 2006-09-10 | 2015-05-29 | Glycotope Gmbh | Uporaba človeških celic izvirajočih iz mieloične levkemije za izražanje protiteles |
| EP1920781B1 (en) * | 2006-11-10 | 2015-03-04 | Glycotope GmbH | Compositions comprising a core-1 positive microorganism and their use for the treatment or prophylaxis of tumors |
| EP2281844A1 (en) | 2009-07-31 | 2011-02-09 | Glycotope GmbH | MUC 1 antibodies |
| US8518405B2 (en) | 2009-10-08 | 2013-08-27 | The University Of North Carolina At Charlotte | Tumor specific antibodies and uses therefor |
| WO2012020065A1 (en) | 2010-08-10 | 2012-02-16 | Glycotope Gmbh | Fab-glycosylated antibodies |
| US9845362B2 (en) | 2010-10-08 | 2017-12-19 | The University Of North Carolina At Charlotte | Compositions comprising chimeric antigen receptors, T cells comprising the same, and methods of using the same |
| ES2686313T3 (es) | 2011-08-22 | 2018-10-17 | Glycotope Gmbh | Microorganismos que portan un antígeno tumoral |
| CN103848890B (zh) * | 2012-11-30 | 2015-09-09 | 北京市结核病胸部肿瘤研究所 | Muc1自身抗体识别的抗原多肽 |
| CN105008550B (zh) | 2013-03-01 | 2018-03-30 | 学校法人埼玉医科大学 | 包含对muc4基因多态性进行检测的步骤的、判定抗癌剂疗法的副作用的发生风险的方法 |
| US10208125B2 (en) * | 2013-07-15 | 2019-02-19 | University of Pittsburgh—of the Commonwealth System of Higher Education | Anti-mucin 1 binding agents and uses thereof |
| RU2016133593A (ru) * | 2014-02-06 | 2018-03-07 | Медисинал Кемистри Фармасьютикал Ко., Лтд. | Антитело против гликопептида муцина 4 (muc4) и его применение |
| AU2015254257B2 (en) * | 2014-04-28 | 2021-02-25 | Medicinal Chemistry Pharmaceuticals, Co., Ltd. | Anti-MUC1 antibody or antigen-binding fragment of same, and use thereof |
| WO2016026143A1 (en) | 2014-08-22 | 2016-02-25 | Huiru Wang | Saccharide-based biomarkers and therapeutics |
| US11554181B2 (en) | 2014-09-05 | 2023-01-17 | The University Of North Carolina At Charlotte | Tumor specific antibody conjugates and uses therefor |
| CA2976089C (en) | 2015-02-10 | 2026-01-13 | Minerva Biotechnologies Corporation | Humanized anti-muc1* antibodies |
| WO2017139975A1 (en) | 2016-02-19 | 2017-08-24 | Huiru Wang | Antibodies against n-acetylglucosamine and n-acetyl-galactosamine |
| TWI780082B (zh) | 2016-11-18 | 2022-10-11 | 日商安斯泰來製藥股份有限公司 | 新穎抗人類ＭＵＣ１抗體Ｆａｂ片段 |
| CN112105384B (zh) * | 2017-01-18 | 2024-08-23 | 苏州启航纳米药物有限公司 | 癌糖肽的单克隆和人源化抗体 |
| CA3050039A1 (en) * | 2017-01-27 | 2018-08-02 | Glycotope Gmbh | Anti-cancer treatments with an anti-muc1 antibody and an erbb inhibitor |
| CA3055433A1 (en) | 2017-03-29 | 2018-10-04 | Glycotope Gmbh | Humanized anti-cd40 antibodies |
| CN111315776A (zh) * | 2017-03-29 | 2020-06-19 | 葛莱高托普有限公司 | Pd-l1和ta-muc1抗体 |
| AU2018241781A1 (en) * | 2017-03-29 | 2019-07-18 | Glycotope Gmbh | Multispecific antibody constructs binding to MUC1 and CD3 |
| TWI795415B (zh) | 2017-07-07 | 2023-03-11 | 日商安斯泰來製藥股份有限公司 | 新穎的抗人類ＣＥＡＣＡＭ５抗體Ｆａｂ片段 |
| IL301637B2 (en) | 2017-09-29 | 2024-10-01 | Daiichi Sankyo Co Ltd | Antibody-pyrrolobenzodiazepine derivative conjugate |
| US12605469B2 (en) | 2017-10-02 | 2026-04-21 | The University Of North Carolina At Charlotte | Tumor specific antibody conjugates and uses therefor |
| US11161911B2 (en) | 2017-10-23 | 2021-11-02 | Go Therapeutics, Inc. | Anti-glyco-MUC1 antibodies and their uses |
| MX2020004220A (es) * | 2017-10-24 | 2020-10-05 | Go Therapeutics Inc | Anticuerpos anti-glico-muc1 y sus usos. |
| JP2021514625A (ja) * | 2018-03-01 | 2021-06-17 | グリコトープ ゲーエムベーハー | 抗ｍｕｃ１抗体およびｉｌ−１５を含む融合タンパク質構築物 |
| MX2020012351A (es) * | 2018-05-17 | 2021-01-29 | Astellas Pharma Inc | Complejo que tiene fragmento fab de anticuerpo anti-muc1 de humano, enlazador peptido y/o ligando. |
| HUE067382T2 (hu) | 2018-05-18 | 2024-10-28 | Daiichi Sankyo Co Ltd | Anti-MUC1-exatecan antitest-hatóanyag konjugátum |
| CN108982854B (zh) * | 2018-06-19 | 2021-07-27 | 哈尔滨医科大学 | 蛋白质muc13在制备诊断肝内胆管癌的试剂中的应用 |
| JP7541930B2 (ja) * | 2018-06-29 | 2024-08-29 | ジーオー セラピューティクス，インコーポレイテッド | 抗グリコｍｕｃ１抗体およびその使用 |
| CA3115747A1 (en) | 2018-10-10 | 2020-04-16 | Astellas Pharma Inc. | Pharmaceutical composition containing tagged site-antihuman antibody fab fragment complex |
| EP3950061A4 (en) | 2019-03-25 | 2022-11-16 | Daiichi Sankyo Company, Limited | ANTIBODY PYRROLOBENZODIAZEPINE DERIVATIVE CONJUGATE |
| TWI841715B (zh) | 2019-03-27 | 2024-05-11 | 日商第一三共股份有限公司 | 抗體-吡咯并苯二氮呯衍生物結合物及ｐａｒｐ抑制劑之組合及其用途 |
| AU2022420709A1 (en) * | 2021-12-21 | 2024-08-01 | Merus B.V. | Binding domains against cancer-associated muc1 |
| EP4536278A2 (en) | 2022-06-07 | 2025-04-16 | Actinium Pharmaceuticals, Inc. | Bifunctional chelators and conjugates |
| TW202506190A (zh) | 2023-04-05 | 2025-02-16 | 日商第一三共股份有限公司 | 利用抗ｍｕｃ１抗體－藥物結合物投予的藥劑低敏感性癌之治療方法 |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5683674A (en) | 1987-01-07 | 1997-11-04 | Imperial Cancer Research Technology Ltd. | Antibody against human mucin core protein and method of preparing and using same |
| EP0636029B1 (en) | 1992-04-13 | 2000-11-08 | Dana-Farber Cancer Institute, Inc. | Antibodies specific for carcinoma-associated antigens |
| US5804187A (en) | 1992-11-16 | 1998-09-08 | Cancer Research Fund Of Contra Costa | Modified antibodies with human milk fat globule specificity |
| US5739277A (en) | 1995-04-14 | 1998-04-14 | Genentech Inc. | Altered polypeptides with increased half-life |
| US6465220B1 (en) * | 1998-12-21 | 2002-10-15 | Glycozym Aps | Glycosylation using GalNac-T4 transferase |
| ATE290879T1 (de) | 1999-08-18 | 2005-04-15 | Altarex Medical Corp | Therapeutische antikörper gegen das muc-1 antigen und verfahren zu deren verwendung |
| US7147850B2 (en) | 1999-08-18 | 2006-12-12 | Altarex Medical Corp. | Therapeutic binding agents against MUC-1 antigen and methods for their use |
| GB0029360D0 (en) | 2000-12-01 | 2001-01-17 | Univ Nottingham | Humanised antibodies and uses thereof |
| AU2003266236A1 (en) | 2002-07-22 | 2004-02-09 | Nemod Immuntherapie Ag | Method for the production of an immunostimulating mucin (muc1) |
| SI1530628T1 (sl) | 2002-08-16 | 2011-02-28 | Glycotope Gmbh | Postopek za proizvodnjo s temperaturo induciranih lizatov tumorskih celic za uporabo kot imunogenske spojine |
| DE10303664A1 (de) * | 2003-01-23 | 2004-08-12 | Nemod Immuntherapie Ag | Erkennungsmoleküle zur Behandlung und Detektion von Tumoren |
| ES2425475T3 (es) | 2003-08-18 | 2013-10-15 | Glycotope Gmbh | Líneas de células tumorales NM-F9 (DSM ACC2606) y NM-D4 (DSM ACC2605), usos de las mismas |
| EP1725673A1 (en) | 2004-02-13 | 2006-11-29 | Glycotope Gmbh | Sialytated glycoproteins-process conditions and an efficient method for their production |
| SI2073842T1 (sl) | 2006-09-10 | 2015-05-29 | Glycotope Gmbh | Uporaba človeških celic izvirajočih iz mieloične levkemije za izražanje protiteles |
| EP2281844A1 (en) | 2009-07-31 | 2011-02-09 | Glycotope GmbH | MUC 1 antibodies |
-
2009
- 2009-07-31 EP EP09009942A patent/EP2281844A1/en not_active Withdrawn
-
2010
- 2010-07-28 AR ARP100102737A patent/AR077334A1/es not_active Application Discontinuation
- 2010-07-30 NZ NZ597563A patent/NZ597563A/xx unknown
- 2010-07-30 US US13/387,587 patent/US9217038B2/en active Active
- 2010-07-30 AU AU2010278302A patent/AU2010278302B2/en active Active
- 2010-07-30 JP JP2012522029A patent/JP5922018B2/ja active Active
- 2010-07-30 KR KR1020127005121A patent/KR101773506B1/ko active Active
- 2010-07-30 EA EA201270207A patent/EA029954B1/ru unknown
- 2010-07-30 SG SG2012000865A patent/SG177527A1/en unknown
- 2010-07-30 MX MX2012000874A patent/MX2012000874A/es active IP Right Grant
- 2010-07-30 EP EP10746999A patent/EP2459595A1/en not_active Withdrawn
- 2010-07-30 WO PCT/EP2010/004663 patent/WO2011012309A1/en not_active Ceased
- 2010-07-30 EP EP18181262.9A patent/EP3421497A1/en not_active Withdrawn
- 2010-07-30 BR BR112012002226A patent/BR112012002226A2/pt not_active Application Discontinuation
- 2010-07-30 SG SG10201404019XA patent/SG10201404019XA/en unknown
- 2010-07-30 CN CN201080033969.9A patent/CN102574926B/zh active Active
- 2010-07-30 CA CA2768888A patent/CA2768888C/en active Active
-
2012
- 2012-01-09 ZA ZA2012/00166A patent/ZA201200166B/en unknown
- 2012-01-30 CU CU2012000019A patent/CU23972B1/es active IP Right Grant
- 2012-01-30 IL IL217827A patent/IL217827A/en active IP Right Grant
-
2016
- 2016-01-04 JP JP2016000133A patent/JP6272916B2/ja active Active
Also Published As
| Publication number | Publication date |
|---|---|
| EP2281844A1 (en) | 2011-02-09 |
| SG10201404019XA (en) | 2014-09-26 |
| EA201270207A1 (ru) | 2012-07-30 |
| CN102574926A (zh) | 2012-07-11 |
| KR20120051724A (ko) | 2012-05-22 |
| AR077334A1 (es) | 2011-08-17 |
| BR112012002226A2 (pt) | 2016-11-08 |
| MX2012000874A (es) | 2012-02-01 |
| CA2768888A1 (en) | 2011-02-03 |
| IL217827A0 (en) | 2012-03-29 |
| AU2010278302A1 (en) | 2012-02-09 |
| US9217038B2 (en) | 2015-12-22 |
| JP2016041771A (ja) | 2016-03-31 |
| ZA201200166B (en) | 2013-03-27 |
| CN102574926B (zh) | 2014-10-15 |
| IL217827A (en) | 2017-05-29 |
| CA2768888C (en) | 2019-02-26 |
| EP2459595A1 (en) | 2012-06-06 |
| JP5922018B2 (ja) | 2016-05-24 |
| EP3421497A1 (en) | 2019-01-02 |
| JP2013500703A (ja) | 2013-01-10 |
| KR101773506B1 (ko) | 2017-08-31 |
| SG177527A1 (en) | 2012-02-28 |
| JP6272916B2 (ja) | 2018-01-31 |
| CU23972B1 (es) | 2013-12-27 |
| EA029954B1 (ru) | 2018-06-29 |
| CU20120019A7 (es) | 2012-06-21 |
| US20120128676A1 (en) | 2012-05-24 |
| WO2011012309A1 (en) | 2011-02-03 |
| AU2010278302B2 (en) | 2014-12-18 |
| WO2011012309A8 (en) | 2011-04-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NZ597563A (en) | Muc1 antibodies | |
| AU2018256487A1 (en) | Antibodies that bind to TL1A and their uses | |
| WO2009048537A3 (en) | Humanized antibody | |
| NZ599140A (en) | Antibodies that specifically bind to the epha2 receptor | |
| WO2009048538A3 (en) | Use of anti-amyloid beta antibody in ocular diseases | |
| EA201190132A1 (ru) | Гуманизированные антитела, связывающиеся с cd19, и их применение | |
| PH12016501691A1 (en) | Antibodies to matrix metalloproteinase 9 | |
| WO2009048539A3 (en) | Use of anti-amyloid beta antibody in ocular diseases | |
| NZ594682A (en) | Fully human antibodies specific to cadm1 | |
| PH12016500658A1 (en) | Human anti-alpha-synuclein autoantibodies | |
| NZ717847A (en) | Human antigen binding proteins that bind beta-klotho, fgf receptors and complexes thereof | |
| EA200970694A1 (ru) | ПЭГИЛИРОВАННЫЕ Fab-ФРАГМЕНТЫ АНТИТЕЛ К ПЕПТИДУ Aβ | |
| MX357193B (es) | Moleculas de union anti-alfa sinucleina. | |
| EA201290173A1 (ru) | Антитела против эндоглина | |
| MX2018008680A (es) | Moleculas de union especifica a proteina de union a adn de respuesta transactiva de 43 kda (tdp-43). | |
| EA032189B9 (ru) | Изолированные человеческие моноклональные антитела против ингибитора пути тканевого фактора (tfpi) и фармацевтическая композиция, содержащая их | |
| IL212056A0 (en) | Monoclonal antibodies and methods for their use in the detection of cervical disease | |
| GB201005064D0 (en) | Biological products | |
| MX365387B (es) | Anticuerpos específicos de polipéptido amiloide de islote humano (hiapp) y sus usos. | |
| TN2012000466A1 (en) | Humanized anti cxcr4 antibodies for the treatment of cancer | |
| NZ597611A (en) | Anti notch-1 antibodies | |
| MX340350B (es) | Proteinas de union a antigeno especificas para el componente p amiloide serico. | |
| MX2009008754A (es) | Anticuerpos novedosos contra igf-1r. | |
| UA108207C2 (xx) | Високоафінне людське антитіло до людського ангіопоетину-2 | |
| MX360580B (es) | Autoanticuerpos humanos anti-alfa-sinucleina. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PSEA | Patent sealed | ||
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 3 YEARS UNTIL 30 JUL 2017 BY PAVIS EG Effective date: 20140724 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 30 JUL 2018 BY PAVIS GMBH Effective date: 20170721 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 30 JUL 2019 BY PAVIS GMBH Effective date: 20180720 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 30 JUL 2020 BY PAVIS GMBH Effective date: 20190717 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 30 JUL 2021 BY PAVIS PAYMENTS GMBH Effective date: 20200724 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 30 JUL 2022 BY PAVIS PAYMENTS GMBH Effective date: 20210721 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 30 JUL 2023 BY PAVIS PAYMENTS GMBH Effective date: 20220720 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 30 JUL 2024 BY PAVIS PAYMENTS GMBH Effective date: 20230718 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 30 JUL 2025 BY PAVIS PAYMENTS GMBH Effective date: 20240715 |
|
| ASS | Change of ownership |
Owner name: DAIICHI SANKYO COMPANY, JP Effective date: 20250507 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 30 JUL 2026 BY PAVIS PAYMENT GMBH Effective date: 20250718 |